Stock Buzz: Earth Science Tech Inc (ETST), Scotts Miracle-Gro Co (SMG), AbbVie Inc (ABBV)
Earth Science Tech Inc (OTCMKTS:ETST) reported the plunge of -1.05% and closed at $1.88, with the total traded volume of 0.00 shares. During last trade its minimum price was $1.59 and it gained its highest price of $2.04 and has a total of 40.91 million outstanding shares.
On March 27, 2017 Earth Science Tech, Inc. (ETST), an innovative biotech company focused on cannabis (industrial hemp) and cannabinoid research and development, nutraceuticals, pharmaceuticals, and medical devices, and its two subsidiaries – Earth Science Pharmaceutical Inc. and Cannabis Therapeutics inc. – are proud to announce the projected timeline for the delivery of its MSN-2 medical device; the negotiation of a strategic partnership with Connexions Commerciales Internationales ct, Inc.; and the beginning of negotiations with partners in Africa and Japan.
The MSN-2medica device was announced in November 2016, (https://globenewswire.com/news-release/2016/11/21/891699/0/en/ETST-Announces-60-Patient-Clinical-Prelaunch-Study-for-its-MSN-2-Medical-Device-for-the-Diagnosis-of-Chlamydia-Gonorrhea-ETST-Elects-Dr-Michel-Aubé-as-New-CEO-CSO-and-Nickolas-Tabr.html). The above mentioned medical device can be used by women to extract a cell sample from herself, which then is shipped to a proprietary lab for analysis of sexually transmitted infections. Our device is proven to sample for chlamydia and is currently undergoing testing to certify the device for gonorrhea sampling.
ETST will inaugurate the manufacturing facility for the MSN-2 medical device within Q2 2017, and the initial product release for detecting Chlamydia only may begin as soon as Q3 2017. The MSN-2 will be marketed only overseas during the beginning. The FDA and Health Canada approvals required to market a Class II medical device in Canada and the USA require the factory to be ISO-13485 accredited, which will take more time, estimating within 12 to 18 months.
Scotts Miracle-Gro Co (NYSE:SMG) showing dropped of -1.14% and closed at $91.66, after gaining total volume of 0.00 shares. Its earnings per share (EPS) is $4.29 and its beta value stands at 0.64 points and has total market capitalization of $5.51 billion and a total of 59.84 million outstanding shares.
Scotts Miracle-Gro Co (SMG) on March 23, 2017 announced The Scotts Miracle-Gro Foundation as the presenting sponsor of The George Barley Water Prize, the world’s largest water prize offering $10 million to the person or team that develops the most cost-effective technology to remove phosphorus from freshwater bodies.
Together through the Barley Prize, the organizations will combat the issue of harmful algal blooms caused by excess phosphorus, which threatens the health of the Everglades and countless other freshwater bodies.
“Nutrient pollution, especially from phosphorus, is a significant and growing crisis that must be solved,” said Jim King, president of The Scotts Miracle-Gro Foundation. “Our company is proud that we became the largest fertilizer manufacturer in the world to remove phosphorus from our fertilizer products, a step we took in 2011. But we knew then, as we still do today, that our decision would have little impact on eliminating harmful algal blooms that continue to plague freshwater bodies around the world. The decision by our Foundation to announce the sponsorship of the George Barley Water Prize on World Water Day is the first step of a multi-year commitment to elevate public awareness of this issue and celebrate the innovation that will help solve it.”
To date, the Barley Prize has attracted more than 100 teams – a community of innovators, scientists and entrepreneurs – from 13 countries. Currently in Stage 1 of four stages, the grand prize will support innovative and cost-effective technologies that will benefit more than 100,000 miles of rivers and streams and close to 2.5 million acres of lakes, reservoirs and ponds.
Nutrient pollution impacts all 50 U.S. states and often threatens drinking water. It is estimated that this pollution is costing the U.S. economy $2.2 billion annually.
The Phase 1 winner was announced today at national summit titled “Global Freshwater Crisis: Impact and Innovation,” co-sponsored by The Scotts Miracle-Gro Foundation and the Everglades Foundation. Approximately 100 attendees from leading water protection entities attended the event, including Restore America’s Estuaries and the Ontario Ministry for the Environment. The Wetsus NAFRAD project – led by a group of researchers at Delft University of Technology and Wageningen University Research in the Netherlands – was named the Barley Water Prize Stage 1 Winner. The Wetsus team’s innovation technology aims to provide a total solution to nutrient pollution through a method used to recover phosphate from waterways.
AbbVie Inc (NYSE:ABBV) increased 0.73% closed at $66.10 and traded with total volume of 0.00 shares, while the average trading remained 7.05M shares. During last trade its minimum price was $65.24 and it gained the highest price of $66.28. Its market capitalization was $105.29 billion.
AbbVie Inc (ABBV) on March 23, 2017 announced that actress, dancer and Emmy Award-winning choreographer Julianne Hough is helping to raise awareness about endometriosis through a campaign called “Get in the Know about ME in EndoMEtriosis.” The campaign, sponsored by AbbVie, is dedicated to inspiring women to learn about and understand endometriosis, a disease affecting an estimated one in 10 women,1 and to address their symptoms with a healthcare professional. Despite being one of the most common gynecologic disorders in America, there is a lack of awareness and prioritization of endometriosis as an important women’s health issue.
“After I was diagnosed with endometriosis in 2008, I talked about my symptoms with family and close friends and it led some of them to talk to a doctor about their own symptoms,” said Hough, who is best known as a two-time professional champion and judge on Dancing with the Stars. “I am the ME in EndoMEtriosis and I’m here to show women what the face of this chronic and painful disease looks like. Endometriosis is a part of me, and it could be affecting you and many other women in your life.”
Endometriosis is associated with pain symptoms which can be debilitating and may interfere with day-to-day activities. Without proper communication about endometriosis, it may take longer for women to receive a diagnosis. The “Get in the Know” website aims to increase awareness about endometriosis, elevate understanding and facilitate conversations between women and healthcare professionals. Women with endometriosis can suffer for up to six to 10 years before diagnosis2,3. The website features a wide range of information and tools such as an endometriosis checklist, which provides a simple overview of symptoms so women can identify those that apply to them, and a symptoms tracker, meant to help women understand the impact endometriosis symptoms have on their daily lives.